Current Research Trends in Medical Technology and Biomaterials

In this session, leading international experts will report on recent trends and developments in academic research with clear potential to significantly influence patient care in the not too distant future. The talks will concentrate on the potential offered by nanotechnology, innovative processes and novel biomaterials to create new treatment approaches with increasing therapeutic efficiency, specificity and precision, while at the same time reducing invasiveness.

Take home message:
Participants will gain an overview of some cutting edge academic research directions and the expectations regarding their influence on future patient care.

The panel:

  • Michael de Wild, FHNW
  • David Eglin, ADI
  • Katharina Maniura, Empa
  • Erik Schkommodau, FHNW
  • Wendelin Stark, ETH Zurich

⇒ Partners


Health Technology Assessments - A New Reality for Innovation only?

Health Technology Assessments are an unstoppable trend in assessing the benefits of medical technology. Given the rising costs of healthcare this instrument will be used more and more. Producers can save a lot of time and money if they implement a coherent strategy for gathering the data they will need later already in the development phase. The breakout session offers participants an introduction to the field, to current HTA processes in Switzerland, to the demands of clinical planning and in insight into global trends. The session will be rounded off with a podium discussion on the topic.

Take home message:
Proactive planning of data collection is the key to successful HTA

The panel:

  • Urs Brügger, ZHAW
  • Beat Egli, Zimmer Biomet GmbH
  • Markus Gnägi, Santésuisse
  • Simon Hölzer, Swiss DRG
  • Markus Ott, Ascensia Diabetes Care Switzerland AG
  • Stefan Otto, BAG
  • Henrik Pfahler, Inselspital
  • Hansjörg Riedwyl, ISS Integrated Scientific Services AG
  • Fabian Stadler, Johnson&Johnson Switzerland
  • Dominik Straumann, B. Braun Medical AG
  • Gabor Szekely, CTI
  • Markus Trutmann, fmCh
  • Peter Wehrheim, Abbott AG
  • Barbara Züst, SPO


Success through Partnerships

When we think of partnerships, we tend to think of large-scale cooperations with a strong media impact, or joint ventures between businesses. But in the Swiss medtech sector, dominated by SMEs, other forms of cooperation are more suited. The breakout session is rounded off with an overview of possible forms of partnership and a few actual examples. A joint approach should help potential partners achieve more innovation and stronger growth. In light of the upcoming changes through the digitalisation of traditional business models, having a strong companion is one of mastering future challenges.

Take home message:
How does a partnership need to be structured to be more successful than if two firms were operating independently? Who is open to collaborate with other companies?

The panel:

  • Joachim Brand, Roche Diagnostics International AG
  • Gino Burro, Zühlke Engineering AG
  • Radi Hofstetter, Hamilton AG
  • Harald Kraushaar, Volpi AG
  • Thomas Kuoni, Stemcup Medical Products AG
  • Martin Schmidt, Jossi Orthopedics Ltd.


How digitalisation drives change in the medtech industry

The fourth industrial revolution is already under way. And yet many businesses are still asking themselves if it is something that affects them. The fact is that it has long since ceased to be enough to produce good products. Value chains and business models are subject to a fundamental change. Opportunities and risks must be weighed up. Each business must ask itself what added value it can offer its customers in future with the help of digital business models.

Take home message:
What is understood by ‘The fourth industrial revolution’?
What influence does digitalisation have on the business models of medtech companies?
How are Swiss SMEs dealing with the issue?

The panel:

  • Andreas Abel, BÜHLMANN Laboratories AG
  • Christian Frei, InspiredView GmbH
  • Immo Oliver Paul, Independent Consultant
  • Andy Tonazzi, konplan systemhaus AG
  • Georg von der Ropp, BMI Lab AG


Intellectual Property & Market Protection

The protection of intellectual property and brands in the field of medical technology is generally experiencing a period of great change from a legal perspective and in a political context. It is becoming increasingly challenging and costly for small and large medtech firms alike to enforce their patents for research, development and products. As a result it is worth considering when to keep know-how as an in-house asset and trade secret.

Take home message:
Using practical examples participants should discuss and eventually share best practices what to bear in mind in terms of patent protection, publications, building international business, or even trade IP rights as well as brands.

The panel:

  • Thomas Dibke, InvenComm GmbH
  • Beat Lechmann, DePuy Synthes Companies
  • Eric R. Perucco, MedBrainTec AG